178 related articles for article (PubMed ID: 16170194)
21. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma.
Eve HE; Furtado MV; Hamon MD; Rule SA
J Clin Oncol; 2009 Nov; 27(32):e189-90; author reply e191. PubMed ID: 19805667
[No Abstract] [Full Text] [Related]
22. [Disappearance of CD 20 after treatment with rituximab of mantle cell lymphoma].
Yoshida K; Kayano H; Shimada T; Wakao D; Takahashi N; Sugahara Y; Yagasaki F; Ito Y; Kawai N; Matsuda A; Suzuki T; Bessho M
Rinsho Ketsueki; 2003 Mar; 44(3):174-81. PubMed ID: 12722344
[TBL] [Abstract][Full Text] [Related]
23. Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma.
Lee J; Kim WS; Kim K; Ahn JS; Jung CW; Lim HY; Kang WK; Park K; Ko YH; Kim YH; Park C; Yoon SH; Lee WY; Chun HK
Leuk Res; 2007 Mar; 31(3):359-64. PubMed ID: 16930692
[TBL] [Abstract][Full Text] [Related]
24. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
[TBL] [Abstract][Full Text] [Related]
25. Mantle cell lymphoma in Thai patients.
Intragumtornchai T; Rojnuckarin P; Sutcharitchan P; Wannakrairot P
J Med Assoc Thai; 2004 Sep; 87(9):1071-5. PubMed ID: 15516008
[TBL] [Abstract][Full Text] [Related]
26. [Duodenal polyposis disclosing mantle-cell lymphoma].
Moulin O; Boucher E; Samson T; Coutant G; Helie C; Algayres JP
Gastroenterol Clin Biol; 2002 Nov; 26(11):1055. PubMed ID: 12483144
[No Abstract] [Full Text] [Related]
27. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors.
Yong W; Zheng W; Zhu J; Zhang Y; Wei Y; Wang X; Lin N; Xie Y; Xu B; Li J
Hematol Oncol; 2006 Mar; 24(1):28-32. PubMed ID: 16323259
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
[TBL] [Abstract][Full Text] [Related]
29. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy.
Kim SJ; Lee SJ; Choi IY; Park Y; Choi CW; Kim IS; Yu W; Hwang HS; Kim BS
Eur J Haematol; 2008 Sep; 81(3):177-84. PubMed ID: 18510703
[TBL] [Abstract][Full Text] [Related]
30. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
Micallef IN; Kahl BS; Maurer MJ; Dogan A; Ansell SM; Colgan JP; Geyer S; Inwards DJ; White WL; Habermann TM
Cancer; 2006 Dec; 107(12):2826-32. PubMed ID: 17099879
[TBL] [Abstract][Full Text] [Related]
31. Is rituximab effective as a single agent in mantle-cell lymphoma?
Grillo-López AJ
Nat Clin Pract Oncol; 2005 Oct; 2(10):500-1. PubMed ID: 16205768
[No Abstract] [Full Text] [Related]
32. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
Liu X; Wang B; Ma X; Guo Y
Jpn J Clin Oncol; 2009 Jul; 39(7):418-24. PubMed ID: 19395464
[TBL] [Abstract][Full Text] [Related]
33. Nonpolypoid intestinal mantle cell lymphoma resembling MALT lymphoma with successful response to rituximab.
D'Antonio A; Boscaino A; Addesso M; Liguori G; Nappi O
South Med J; 2008 Nov; 101(11):1168-9. PubMed ID: 19088534
[TBL] [Abstract][Full Text] [Related]
34. Relapsed non-Hodgkin lymphoma in fraternal twins managed successfully with rituximab maintenance therapy.
Chakravarti A; Leslie WT; Venugopal P
Clin Adv Hematol Oncol; 2005 Feb; 3(2):136-9; discussion 139-40. PubMed ID: 16166983
[No Abstract] [Full Text] [Related]
35. Why R-CHOP for first line treatment of chronic lymphocytic leukemia?
Smolej L
Int J Lab Hematol; 2007 Dec; 29(6):478-9; author reply 479. PubMed ID: 17988306
[No Abstract] [Full Text] [Related]
36. [Treatment of diffuse large B-cell lymphoma].
Gleissner B; Zwick C; Pfreundschuh M
Dtsch Med Wochenschr; 2008 Sep; 133(36):1785-94; quiz 1795-6. PubMed ID: 18767006
[TBL] [Abstract][Full Text] [Related]
37. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
[TBL] [Abstract][Full Text] [Related]
38. Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
Horváth B; Demeter J; Eros N; Hársing J; Csomor J; Matolcsy A; Bottlik G; Gyori G; Marschalkó M; Kárpáti S
J Am Acad Dermatol; 2009 Nov; 61(5):885-8. PubMed ID: 19632742
[TBL] [Abstract][Full Text] [Related]
39. [Antibody therapy in hematology and oncology - part 1].
Kneba M; Schrader C; Köhne H
Med Klin (Munich); 2008 Dec; 103(12):843-59. PubMed ID: 19099214
[No Abstract] [Full Text] [Related]
40. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
